| Date |
Subject |
Media |
| 2025-08-06 |
HanchorBio’s HCB101 Achieves High-Dose Milestone in Clinical Development
|
HanchorBio’s novel immunotherapy drug candidate HCB101 has reached a significant milestone in its Phase I clinical trial. Three patients with advanced solid tumors received a high intravenous dose of 18 mg/kg, and no dose-limiting toxicities or serious adverse events were observed during the monitoring period, demonstrating favorable tolerability. This result was unanimously approved by the Clinical Safety Review Committee at 8:00 PM Taiwan time on July 14, laying a critical foundation for further dose escalation and broader clinical application. |
| 2025-08-06 |
EirGenix Gains Momentum from Contract Fulfillment and CDMO Growth to Boost Second-Half Performance
|
At its investor conference on the 15th, EirGenix announced positive momentum for 2024. Senior Vice President Chang Chih-Jung noted that the number of contracts signed so far this year has already surpassed that of 2023. As these contracts begin to be executed in the third and fourth quarters, along with contributions from the CDMO business, the company expects significant support for its operations in the second half of the year. |
| 2025-08-06 |
Genetics Generation Advancement Builds Smart Laboratory
|
Genetics Generation Advancement (GGA) announced yesterday (16th) that it has signed a strategic cooperation agreement with Lightest Biomedical, a subsidiary of Genomics BioSci & Tech. (GBT), to jointly establish a smart laboratory with AI scalability and compliance management capabilities. This initiative aims to accelerate the development of Lightest Biomedical’s new antibiotics and novel drugs for Parkinson’s disease, with an Investigational New Drug (IND) application to the U.S. expected by 2026. |
| 2025-08-06 |
Gongwin Biopharm's Lung Cancer Drug PTS302 Expands into Malaysia and Taiwan, Accelerating Development in the Asia-Pacific Market
|
Gongwin Biopharm (Gongwin-KY) announced yesterday (16th) that its subsidiary, Gongwin Biopharm Taiwan, has secured two key licensing deals for its lung cancer drug PTS302. |
| 2025-08-06 |
Senhwa Biosciences’ New Drug Program Sponsored by U.S. NCI: First Monotherapy Clinical Trial Begins Patient Enrollment
|
Senhwa Biosciences announced yesterday (July 16) that its investigational new drug Pidnarulex (CX-5461) has been selected for a five-year cancer treatment program sponsored by the U.S. National Cancer Institute (NCI). The first clinical trial under this program—evaluating Pidnarulex as a monotherapy for advanced solid tumors—has successfully enrolled its first patient at the NIH Clinical Center in Bethesda, Maryland, USA. The NCI will fund the clinical trial with an estimated budget of USD 4.8 million, significantly reducing Senhwa's R&D burden and accelerating drug development. |
| 2025-08-06 |
Acer’s Medical Spinoff Develops New AI Healthcare Application
|
Acer Medical, a spinoff of Acer focusing on AI in healthcare, has achieved another milestone in its AI strategy. On July 16, the company announced a partnership with Japan’s Fujitsu to co-develop a new solution named “aiGait powered by UvanceAI.” The solution utilizes Fujitsu’s high-precision AI skeletal recognition technology to analyze patients’ physical movements and gait abnormalities, helping healthcare professionals detect early signs of dementia and Parkinson’s disease, thereby improving clinical diagnosis and intervention efficiency. Acer Medical plans to roll out the solution across elderly care institutions and primary clinics in Taiwan by the end of this year. |
| 2025-08-06 |
Preventing Hospital-Acquired Infections: TYGH and NHRI Jointly Develop “Blind-Spot-Free” Hand Hygiene Monitoring System
|
Hand hygiene is a key measure in preventing infections—especially critical within hospital settings. During the COVID-19 pandemic, Taoyuan General Hospital, Ministry of Health and Welfare (TYGH), experienced a major nosocomial outbreak that led to a 42-day shutdown. In response, the hospital collaborated with the Institute of Biomedical Engineering and Nanomedicine at the National Health Research Institutes (NHRI) to develop the world’s first non-camera, de-identified hand hygiene monitoring system. This innovative system was validated in the hospital’s intensive care units (ICUs) with an accuracy rate of 70% and was featured on the cover of the international journal Global Challenges in December last year. |
| 2025-08-06 |
Ministry of Digital Affairs to Launch Taiwan Sovereign AI Corpus in Q4
|
The Ministry of Digital Affairs has proposed the “Data Innovation and Utilization Promotion Act” and held a briefing on July 15 to explain key aspects of the draft legislation. Among the highlights is the plan to build Taiwan’s sovereign AI corpus by establishing standard licensing terms and conducting data inventories across government agencies. The corpus is scheduled to launch in the fourth quarter. |
| 2025-08-06 |
Leadtek Biomed Chairman Appointed: ADATA Takes 41% Stake, K.S. Lu to Serve as CEO and Drive IPO Efforts
|
Leadtek Biomed, a biotech subsidiary of Leadtek, recently raised NT$100 million in capital and brought in high-profile strategic partners. Memory giant ADATA acquired a 41% stake, becoming the largest shareholder. ADATA Chairman Simon Chen has taken over as Chairman of Leadtek Biomed from Leadtek’s Chairman K.S. Lu. The company registration update was completed at the end of June. |
| 2025-08-06 |
Government Policy Fully Backing Taiwan Innovation Board’s Push Toward Becoming the “Nasdaq of Asia”
|
Chairman of the Taiwan Stock Exchange (TWSE), Lin Hsiu-Ming, stated on the 15th that the Exchange will continue to refine the Innovation Board's framework and dedicate more resources to realizing its goal of becoming the “Nasdaq of Asia” and a cradle for the next wave of unicorns. These efforts are aimed at fostering a globally competitive, flexible, and innovation-friendly regulatory environment, positioning Taiwan as a rising hub for emerging industries and international investors. |
